ArticleVeterinary and comparative oncology2025
Half-Body Radiation Therapy Results in a Prolonged Progression-Free Interval in Canine High-Grade Lymphoma After First Remission.
Article in Veterinary and comparative oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Survival outcomes of dogs with multicentric lymphoma treated with sequential half-body radiotherapy and L-CHOP without maintenance chemotherapy.Journal of veterinary internal medicine · 2026Article
- Combined half-body irradiation and chemotherapy for two dogs with relapsed high-grade B-cell lymphoma.The Journal of veterinary medical science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An optimal protocol of adding wide-field irradiation to multi-agent chemotherapy for dogs with lymphoma has not been established. The aim of this retrospective case-control study was to evaluate the efficacy of a protocol combining chemotherapy and half-body irradiation (HBI) for dogs with high-grade lymphoma. Dogs in the treatment group received cranial HBI 2 weeks after completing the second cycle of the multi-agent chemotherapy protocol. The radiation therapy protocol consisted of 4 Gy/fraction once per day for 2 consecutive days for the cranial half body, followed by the same protocol for the caudal half 2 weeks later. The control group only received multi-agent chemotherapy. All patients were required to have cytological confirmation of high-grade lymphoma and achieve complete remission after two cycles of multi-agent chemotherapy. Fourteen patients receiving HBI and 11 patients in the control group were included. The median progression-free interval (PFI) in the HBI group (1143 days) was significantly longer than that in the control group (316 days, p = 0.004). In the HBI group, dogs with T cell lymphoma had statistically shorter PFI (292 days) than dogs with B cell lymphoma (2127 days, p = 0.0013). The median survival time in the HBI group (1924 days) was significantly longer than that in the chemotherapy-only group (566 days, p = 0.0077). The predictive factors for longer PFI and ST were found in the patients who received HBI and chemotherapy (p = 0.0062 and 0.0252, respectively). For chemotherapy-responding patients that completed a multi-agent protocol, HBI significantly prolonged the time to tumour relapse compared with the chemotherapy-only group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.